American Healthcare REIT, Inc. (NYSE: AHR; the “Company”) announced today that it has commenced an underwritten public offering of 8,100,000shares of its common stock on a forward basis in connection with the forward sale agreement described below. https://mma.prnewswire.com/media/1641068/American_Healthcare_REIT_logo.jpg RBC Capital Markets is acting as the underwriter for the offering. In connection with the offering, the […]

Stepan Company(NYSE:SCL) today announced the successful closing, on November 14, 2025, of the sale of its subsidiary, Stepan Philippines Quaternaries, Inc. (SPQI), manufacturing assets located in Bauan, Batangas, Philippines to Masurf, Inc., a subsidiary of Musim Mas Holdings Pte. Ltd. This transaction fulfills SPQI's previously announced Asset Transfer Agreement, dated May 27, 2025, and underscores

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension GlobeNewswire November 20, 2025 Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”),

(NASDAQ:PRAX), BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug Tsao will host an expert call on Deep Dive into Praxis' Ulixacaltamide

(NASDAQ:KTTA),(NASDAQ:KTTAW), — Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months — — A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable disease and remains on trial for more than 6 months — —

(NasdaqGM:KROS), LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price

(NASDAQ:OLMA), SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock,

(NASDAQ:CGTX), PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi will participate in an “unplugged” fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December

Praxis Precision Medicines to Participate in Upcoming Fireside Chat GlobeNewswire November 20, 2025 BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study GlobeNewswire November 20, 2025 — Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months